
Mavenir and EdgeQ Introduce Industry’s First Software-Defined 4G and 5G Next Generation Small Cells for Neutral Host and Urban Densification

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma





